IXICO (FRA:PYPB) FCF Margin % : -58.54% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is IXICO FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. IXICO's Free Cash Flow for the six months ended in Mar. 2024 was €-1.74 Mil. IXICO's Revenue for the six months ended in Mar. 2024 was €2.97 Mil. Therefore, IXICO's FCF Margin % for the quarter that ended in Mar. 2024 was -58.54%.

As of today, IXICO's current FCF Yield % is -70.99%.

The historical rank and industry rank for IXICO's FCF Margin % or its related term are showing as below:

FRA:PYPB' s FCF Margin % Range Over the Past 10 Years
Min: -44390 Med: -16.84 Max: 8.13
Current: -40.1

During the past 13 years, the highest FCF Margin % of IXICO was 8.13%. The lowest was -44390.00%. And the median was -16.84%.

FRA:PYPB's FCF Margin % is ranked better than
63.58% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs FRA:PYPB: -40.10

IXICO FCF Margin % Historical Data

The historical data trend for IXICO's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO FCF Margin % Chart

IXICO Annual Data

Trend

Sep13

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

FCF Margin %

Get a 7-Day Free Trial

-8.56

8.13

-16.77

-9.50

-24.92

IXICO Semi-Annual Data
	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-21.70	0.63	-23.22	-26.48	-58.54

Competitive Comparison of IXICO's FCF Margin %

For the Biotechnology subindustry, IXICO's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IXICO's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's FCF Margin % distribution charts can be found below:

* The bar in red indicates where IXICO's FCF Margin % falls into.

IXICO FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

IXICO's FCF Margin for the fiscal year that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2023 )	/	Revenue (A: Sep. 2023 )
	=	-1.926	/	7.729
	=	-24.92 %

IXICO's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-1.737	/	2.967
	=	-58.54 %

IXICO FCF Margin % Related Terms

Thank you for viewing the detailed overview of IXICO's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

IXICO (FRA:PYPB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (FRA:PYPB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PHYOF:USA IXI:UK

Address

15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website

https://www.ixico.com

IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (FRA:PYPB) Headlines

No Headlines